Aquila's pre-clinical core services focus on Immuno-Oncology, Immunology and Multiplex Histology services with therapeutic relevance for Oncology, Biomarker Discovery and Target Expression, covering a wide range of in vitro and in vivo proof-of-concept studies. Services investigating the effects of novel compounds provide high-value data to define both compound efficacy and mechanism of action, speeding up and enhancing your drug discovery pipeline. The company designs bespoke in vitro immune cell-based assays, in conjunction with client objectives, to focus on target pathways and potentially identify clinical relevance in the immuno-oncology arena.
Aquila is continually expanding its therapeutic portfolio, please see the Research section for more details. Please feel free to contact us for more information on our therapeutic areas or development activities.
MS is an autoimmune demyelinating disease that, in the majority of patients, evolves into a chronic neurodegenerative disease retaining an inflammatory component. As such, MS sits at the interface of immunology, inflammation and neuroscience. Read More >
Asthma is an increasingly common disorder, particularly in industrialised countries where incidence and mortality are on the increase. Rheumatoid arthritis is a chronic condition causing pain swelling and stiffness in the joints caused by synovial inflammation leading to bone and cartilage damage. Read More >
Inflammatory skin disorders include a wide range of conditions ranging in severity, from mild itching to more serious complications. Concurrently, the increasing use of immunomodulatory drugs for the treatment of other autoimmune diseases has seen a rise in the numbers of Adverse Drug Reactions which most commonly include skin eruptions. Read More >